Evaluation of exjade effect & combination therapy with deferoxamine in patients with thalassemia major

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150119020715N4

Enrollment

Registered

2017-12-17

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia. Thalassemia

Interventions

Intervention 1: Group 1: treated with exjade daily 30 mg / kg single dose of fasting in the morning. Intervention 2: Group 2: In addition to exjade, deferral ampoule 50 mg / kg subcutaneously with des

Treatment - Drugs

Group 1: treated with exjade daily 30 mg / kg single dose of fasting in the morning

Group 2: In addition to exjade, deferral ampoule 50 mg / kg subcutaneously with desferal pump

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Children over 5 years old with thalassemia major Exclusion criteria: People under 5 years of age with hepatitis and HIV; patients who do not have a study entry; patients with kidney and liver failure; and no exjade oral tolerance.

Exclusion criteria

Exclusion criteria: Inclusion criteria: Children over 5 years old with thalassemia major Exclusion criteria: People under 5 years of age with hepatitis and HIV; patients who do not have a study entry; patients with kidney and liver failure; and no exjade oral tolerance.

Design outcomes

Primary

Measure	Time frame
Ferritin. Timepoint: 6 months after starting treatment. Method of measurement: blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPooria Shokri

Arak University of Medical sciences

rahenorayaneh@yahoo.com+98 86 3465 5314

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026